People · Operator
Named in public records as an officer, director or promoter · active 2019–2025 · Biotech
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Goodwin Biotechnology, Inc | — | Biotech | Series B | $30.7M | $7.7M | 2019 |
Karl Pinto at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Karl Pinto on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Brandon Price | 1 | 4 |
| Nikhil Puri | 1 | 2 |
| Divya Menezes | 1 | 1 |
| Steven Vorgity | 1 | 1 |
| Darrin Schellin | 1 | 1 |
| SooYoung S. Lee | 1 | 1 |
| Sunil K. Agarwal | 1 | 1 |
| Cesar K. Menezes | 1 | 1 |
| Divya K. Menezes | 1 | 1 |
| Maria Emila Menezes | 1 | 1 |
| Nikhil Emila Puri | 1 | 1 |
| Jerry Emila Liao | 1 | 1 |
| Kent Payne | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.